[
  {
    "ts": "2025-08-01T11:10:00+00:00",
    "headline": "Regeneron cancer bispecific rejected again; Allogene discloses trial death",
    "summary": "The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.",
    "url": "https://www.biopharmadive.com/news/regeneron-odronextamab-crl-allogene-patient-death-bristol-myers-earnings/756464/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "1997eb1b-2933-3051-9968-d6840fc9367b",
      "content": {
        "id": "1997eb1b-2933-3051-9968-d6840fc9367b",
        "contentType": "STORY",
        "title": "Regeneron cancer bispecific rejected again; Allogene discloses trial death",
        "description": "",
        "summary": "The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.",
        "pubDate": "2025-08-01T11:10:00Z",
        "displayTime": "2025-08-01T11:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/regeneron-odronextamab-crl-allogene-patient-death-bristol-myers-earnings/756464/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-cancer-bispecific-rejected-again-111000085.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "ALLO"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-01T11:09:03+00:00",
    "headline": "Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics",
    "summary": "The addition of Zurzuvae is expected to diversify and increase the company's revenue base and cash flow.",
    "url": "https://www.pharmaceutical-technology.com/news/supernus-sage-neuropsychiatric-portfolio/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "0a48f4d2-0d03-389c-b1c3-6dd7cd89594a",
      "content": {
        "id": "0a48f4d2-0d03-389c-b1c3-6dd7cd89594a",
        "contentType": "STORY",
        "title": "Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics",
        "description": "",
        "summary": "The addition of Zurzuvae is expected to diversify and increase the company's revenue base and cash flow.",
        "pubDate": "2025-08-01T11:09:03Z",
        "displayTime": "2025-08-01T11:09:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/0bbdb7589f7acf7faa836b2e4941369e",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "The acquisition includes the FDA-approved capsules and a central nervous system discovery platform. Credit: NMK-Studio/Shutterstock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jGWl68cDrpKwF_fcM.ynFg--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/0bbdb7589f7acf7faa836b2e4941369e.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/D5DRibwYbq8SMufCreUJkA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/0bbdb7589f7acf7faa836b2e4941369e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/supernus-sage-neuropsychiatric-portfolio/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/supernus-strengthens-neuropsychiatric-portfolio-sage-110903814.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SUPN"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "MC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-01T08:00:00+00:00",
    "headline": "Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus",
    "summary": "With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater understanding of its drivers.",
    "url": "https://www.pharmavoice.com/news/merck-alzheimers-disease-tau-comeback-precision-medicine/756517/",
    "source": "Pharma Voice",
    "provider": "yfinance",
    "raw": {
      "id": "c202e170-0ae8-352d-afce-8de279600a7c",
      "content": {
        "id": "c202e170-0ae8-352d-afce-8de279600a7c",
        "contentType": "STORY",
        "title": "Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus",
        "description": "",
        "summary": "With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater understanding of its drivers.",
        "pubDate": "2025-08-01T08:00:00Z",
        "displayTime": "2025-08-01T08:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharma_voice_330/8a3ffc5e20d476f3c78ee9ed63b17c4a",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "A wall showing a Merck & Co. logo in Kenilworth, New Jersey",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2dFn0OrNUmippyPkiqz6Hg--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/8a3ffc5e20d476f3c78ee9ed63b17c4a.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YHvWHuX_XO1_JeGL_mylRg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharma_voice_330/8a3ffc5e20d476f3c78ee9ed63b17c4a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharma Voice",
          "url": "https://www.pharmavoice.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmavoice.com/news/merck-alzheimers-disease-tau-comeback-precision-medicine/756517/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-assembles-alzheimer-comeback-080000534.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "4523.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]